Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research. Norris JL, Caprioli RM (2013) Chem Rev 113: 2309-42 Drug metabolism by Escherichia coli expressing human cytochromes P450. Parikh A, Gillam EM, Guengerich FP (1997) Nat Biotechnol 15: 784-8 MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Cornett DS, Reyzer ML, Chaurand P, Caprioli RM (2007) Nat Methods 4: 828-33 Computational methods in drug discovery. Sliwoski G, Kothiwale S, Meiler J, Lowe EW (2014) Pharmacol Rev 66: 334-95 Molecular basis of ethnic differences in drug disposition and response. Xie HG, Kim RB, Wood AJ, Stein CM (2001) Annu Rev Pharmacol Toxicol 41: 815-50 Cytochrome P-450 3A4: regulation and role in drug metabolism. Guengerich FP (1999) Annu Rev Pharmacol Toxicol 39: 1-17 Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY (2010) Genome Res 20: 1020-36 Guidelines for drug therapy in renal failure. Bennett WM, Singer I, Golper T, Feig P, Coggins CJ (1977) Ann Intern Med 86: 754-83 Matrices for combined delivery of proteins and synthetic molecules. Gilmore KA, Lampley MW, Boyer C, Harth E (2016) Adv Drug Deliv Rev 98: 77-85 A malleable catalyst dominates the metabolism of drugs. Guengerich FP (2006) Proc Natl Acad Sci U S A 103: 13565-6 Identifying mechanism-of-action targets for drugs and probes. Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK (2012) Proc Natl Acad Sci U S A 109: 11178-83 MALDI-MS-based imaging of small molecules and proteins in tissues. Reyzer ML, Caprioli RM (2007) Curr Opin Chem Biol 11: 29-35 Recent Structural Insights into Cytochrome P450 Function. Guengerich FP, Waterman MR, Egli M (2016) Trends Pharmacol Sci 37: 625-640 Macrophage-Targeted Therapeutics for Metabolic Disease. Peterson KR, Cottam MA, Kennedy AJ, Hasty AH (2018) Trends Pharmacol Sci 39: 536-546 Expression of drug-metabolizing enzymes. Guengerich FP, Parikh A (1997) Curr Opin Biotechnol 8: 623-8 Sulfenylation of Human Liver and Kidney Microsomal Cytochromes P450 and Other Drug-Metabolizing Enzymes as a Response to Redox Alteration. Albertolle ME, Phan TTN, Pozzi A, Guengerich FP (2018) Mol Cell Proteomics 17: 889-900 The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D (2011) Clin Pharmacol Ther 89: 784-5 The emerging role of electronic medical records in pharmacogenomics. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, Davis RL, Skaar T, Lamba J, Savova G (2011) Clin Pharmacol Ther 89: 379-86 "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Wandel C, Kim RB, Stein CM (2003) Clin Pharmacol Ther 73: 394-6 Transporters and drug therapy: implications for drug disposition and disease. Ho RH, Kim RB (2005) Clin Pharmacol Ther 78: 260-77 The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. O'Donnell PH, Bush A, Spitz J, Danahey K, Saner D, Das S, Cox NJ, Ratain MJ (2012) Clin Pharmacol Ther 92: 446-9 Intestinal drug transporter expression and the impact of grapefruit juice in humans. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB (2007) Clin Pharmacol Ther 81: 362-70 Pharmacogenomics at the tipping point: challenges and opportunities. Roden DM, Tyndale RF (2011) Clin Pharmacol Ther 89: 323-7 MALDI imaging mass spectrometry--painting molecular pictures. Schwamborn K, Caprioli RM (2010) Mol Oncol 4: 529-38 Cytochromes P450, drugs, and diseases. Guengerich FP (2003) Mol Interv 3: 194-204 Characterization of human cytochrome P450 enzymes. Guengerich FP (1992) FASEB J 6: 745-8 MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue. Cornett DS, Frappier SL, Caprioli RM (2008) Anal Chem 80: 5648-53 Druggability indices for protein targets derived from NMR-based screening data. Hajduk PJ, Huth JR, Fesik SW (2005) J Med Chem 48: 2518-25 Drug Metabolism and Toxicology Special Issue Call for Papers. Guengerich FP, Georg GI, Wang S (2019) J Med Chem 62: 1077 In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds. Mast N, Verwilst P, Wilkey CJ, Guengerich FP, Pikuleva IA (2020) J Med Chem 63: 6477-6488 Characterization of orphan human cytochromes P450. Stark K, Guengerich FP (2007) Drug Metab Rev 39: 627-37 Continuous arteriovenous hemofiltration in acute renal failure. Golper TA (1985) Am J Kidney Dis 6: 373-86 Drug prescribing in renal failure: dosing guidelines for adults. Bennett WM, Aronoff GR, Morrison G, Golper TA, Pulliam J, Wolfson M, Singer I (1983) Am J Kidney Dis 3: 155-93 Orthosteric- and allosteric-induced ligand-directed trafficking at GPCRs. Digby GJ, Conn PJ, Lindsley CW (2010) Curr Opin Drug Discov Devel 13: 587-94 Automated dose-rounding recommendations for pediatric medications. Johnson KB, Lee CK, Spooner SA, Davison CL, Helmke JS, Weinberg ST (2011) Pediatrics 128: e422-8 Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, Goldstein SL, Kidney Health Initiative (2015) Clin J Am Soc Nephrol 10: 159-64 Imaging of intact tissue sections: moving beyond the microscope. Seeley EH, Schwamborn K, Caprioli RM (2011) J Biol Chem 286: 25459-66 Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4. Isin EM, Guengerich FP (2007) J Biol Chem 282: 6863-74 The First 50 Years of Molecular Pharmacology. Brown JH, Catterall WA, Conn PJ, Cull-Candy SG, Dingledine R, Harden TK, Insel PA, Milligan G, Traynelis SF (2015) Mol Pharmacol 88: 139-40 Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Rendic S, Guengerich FP (2010) Curr Drug Metab 11: 4-84
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.